生长激素治疗小于胎龄儿的研究进展

Research progress of growth hormone in the treatment of small for gestational age infants

通常情况下小于胎龄(SGA)儿在出生之后会发生追赶生长,但有部分SGA儿未能表现出足够的追赶生长,导致体格生长落后,并且成年后代谢性疾病风险增加。应用外源性生长激素替代治疗可保证和促进SGA儿追赶生长的发生,但随着生长激素在相关临床疾病发挥疗效的同时,生长激素是否可能带来长期风险亦逐步被临床关注,本文拟对生长激素治疗SGA的疗效和可能风险进行综述。

Generally,small for gestational age(SGA)infants will catch up with growth after birth,but some SGAs fail to show enough catch-up growth,leading to physical growth backwardness,and the risk of metabolic diseases in adult offspring increases.The application of exogenous growth hormone replacement therapy can ensure and promote the occurrence of SGA catching up with growth.However,as growth hormone exerts therapeutic effects in related clinical diseases,clinical attention is gradually being paid to whether growth hormone may bring long-term risks.This article aims to review the efficacy and potential risks of growth hormone treatment for SGA.